Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 10, 2011, Pages 4141-4146

  Christiansen, Ailsa J ^a   West, Alison ^a   Banks, Kellie Marie ^a   Haynes, Nicole M ^a   Teng, Michele W ^a   Smyth, Mark J ^a,b   Johnstone, Ricky W ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Anticancer therapy; Epigenetic regulatory agent; Immunogenic cell death

Indexed keywords

AUTOIMMUNE REGULATOR PROTEIN; CD137 MONOCLONAL ANTIBODY; CD40 LIGAND MONOCLONAL ANTIBODY; GAMMA INTERFERON; MONOCLONAL ANTIBODY; PERFORIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VORINOSTAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELL SURVIVAL; CYTOTOXIC T LYMPHOCYTE; IMMUNE RESPONSE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TUMOR CELL; TUMOR REGRESSION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-PRESENTING CELLS; COMBINED MODALITY THERAPY; HISTONE DEACETYLASE INHIBITORS; HYDROXAMIC ACIDS; MICE; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 79952760874     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1011037108     Document Type: Article

References (43)

1. Johnstone RW, Ruefli AA, Lowe SW (2002) Apoptosis: a link between cancer genetics and chemotherapy. Cell 108:153-164. (Pubitemid 34161136)
2. Zitvogel L, et al. (2008) The anticancer immune response: indispensable for therapeutic success? J Clin Invest 118:1991-2001.
3. Ghiringhelli F, et al. (2009) Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 15: 1170-1178.
4. Aymeric L, et al. (2010) Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res 70:855-858.
5. Ma Y, et al. (2010) Chemotherapy and radiotherapy: Cryptic anticancer vaccines. Semin Immunol 22:113-124.
6. Stagg J, Johnstone RW, Smyth MJ (2007) From cancer immunosurveillance to cancer immunotherapy. Immunol Rev 220:82-101. (Pubitemid 350045568)
7. Pagès F, et al. (2010) Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 29:1093-1102.
8. Swann JB, Smyth MJ (2007) Immune surveillance of tumors. J Clin Invest 117: 1137-1146. (Pubitemid 46718398)
9. Uno T, et al. (2006) Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med 12:693-698. (Pubitemid 43865240)
10. Johnstone RW, Frew AJ, Smyth MJ (2008) The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 8:782-798.
11. Lindemann RK, et al. (2007) Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci USA 104:8071-8076. (Pubitemid 47185877)
12. Ellis L, et al. (2009) The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy. Blood 114:380-393.
13. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769-784. (Pubitemid 44348499)
14. Johnstone RW (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1:287-299.
15. Insinga A, et al. (2005) Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 11:71-76. (Pubitemid 40215840)
16. Maeda T, Towatari M, Kosugi H, Saito H (2000) Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood 96:3847-3856.
17. Magner WJ, et al. (2000) Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J Immunol 165:7017-7024. (Pubitemid 32001174)
18. Manning J, et al. (2008) Induction of MHC class I molecule cell surface expression and epigenetic activation of antigen-processing machinery components in a murine model for human papilloma virus 16-associated tumours. Immunology 123:218-227.
19. Khan AN, Gregorie CJ, Tomasi TB (2008) Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunol Immunother 57:647-654.
20. Araki Y, Fann M, Wersto R, Weng NP (2008) Histone acetylation facilitates rapid and robust memory CD8 T cell response through differential expression of effector molecules (eomesodermin and its targets: perforin and granzyme B). J Immunol 180: 8102-8108.
21. Northrop JK, Wells AD, Shen H (2008) Cutting edge: chromatin remodeling as a molecular basis for the enhanced functionality of memory CD8 T cells. J Immunol 181:865-868.
22. Frew AJ, et al. (2008) Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc Natl Acad Sci USA 105: 11317-11322.
23. Hixon JA, Blazar BR, Anver MR, Wiltrout RH, Murphy WJ (2001) Antibodies to CD40 induce a lethal cytokine cascade after syngeneic bone marrow transplantation. Biol Blood Marrow Transplant 7:136-143. (Pubitemid 32294212)
24. Hixon JA, et al. (2002) Administration of either anti-CD40 or interleukin-12 following lethal total body irradiation induces acute lethal toxicity affecting the gut. Biol Blood Marrow Transplant 8:316-325. (Pubitemid 34784989)
25. Vonderheide RH, et al. (2001) Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol 19:3280-3287. (Pubitemid 32591446)
26. Hayakawa Y, Godfrey DI, Smyth MJ (2004) Alpha-galactosylceramide: potential immunomodulatory activity and future application. Curr Med Chem 11:241-252. (Pubitemid 38128847)
27. Teng MW, et al. (2007) Combined natural killer T-cell based immunotherapy eradicates established tumors in mice. Cancer Res 67:7495-7504. (Pubitemid 47206579)
28. Armeanu S, et al. (2005) Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 65:6321-6329. (Pubitemid 40994418)
29. Skov S, et al. (2005) Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res 65: 11136-11145. (Pubitemid 41713385)
30. Whitecross KF, et al. (2009) Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. Blood 113: 1982-1991.
31. Voskoboinik I, Smyth MJ, Trapani JA (2006) Perforin-mediated target-cell death and immune homeostasis. Nat Rev Immunol 6:940-952. (Pubitemid 44851736)
32. Rasheed W, Bishton M, Johnstone RW, Prince HM (2008) Histone deacetylase inhibitors in lymphoma and solid malignancies. Expert Rev Anticancer Ther 8: 413-432. (Pubitemid 351836289)
33. Bots M, Johnstone RW (2009) Rational combinations using HDAC inhibitors. Clin Cancer Res 15:3970-3977.
34. Frew AJ, Johnstone RW, Bolden JE (2009) Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett 280:125-133.
35. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G (2008) Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8:59-73.
36. Teng MW, Sharkey J, McLaughlin NM, Exley MA, Smyth MJ (2009) CD1d-based combination therapy eradicates established tumors in mice. J Immunol 183: 1911-1920.
37. Ruefli AA, et al. (2001) The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 98:10833-10838. (Pubitemid 32878706)
38. Peart MJ, et al. (2003) Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 63:4460-4471. (Pubitemid 36951018)
39. Lake RA, Robinson BW (2005) Immunotherapy and chemotherapy - a practical partnership. Nat Rev Cancer 5:397-405. (Pubitemid 40637831)
40. Melero I, et al. (1997) Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 3:682-685. (Pubitemid 27264981)
41. Murakami T, et al. (2008) Transcriptional modulation using HDACi depsipeptide promotes immune cell-mediated tumor destruction of murine B16 melanoma. J Invest Dermatol 128:1506-1516. (Pubitemid 351693204)
42. Lundqvist A, et al. (2006) Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res 66:7317-7325. (Pubitemid 44197714)
43. Kato N, et al. (2007) Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells. Leukemia 21:2103-2108.